Innovating Qool Antibodies
Our Mission
Qoolabs is a biotech company that is dedicated to providing innovative antibody products for research, diagnostics and therapeutic drug development. Our team consists of experienced professionals who are passionate about delivering high-quality products and services.
Founded in 2012, Qoolabs has been committed to excellence with focus on delivering the best possible antibodies to our customers. With our core technology QMAb™ quick monoclonal antibody discovery platform, our mission is to provide high-quality antibody solutions empower our clients to reach their full potential and achieve their goals. The QMAb™ platform is designed with extensibility in mind, making it highly customizable to meet the unique needs of each of our clients. Whether you’re searching for antibodies to a small molecule or a large complex, Qoolabs has a solution that can help you to advance your research.
We take pride in our culture of innovation and collaboration, and we believe that this is what sets us apart in the marketplace. If you’re looking for a partner that can help you achieve your goals, we’d love to hear from you.
Technology
The QMAb™ (Quick Monoclonal Antibody from Blood) platform technology enables efficient cloning of antibody light and heavy chain coding DNA from B cells in peripheral blood. Using QMAb™, antibodies have been successfully generated from the blood of rabbits, chickens, and llamas, including single domain VHH nanobodies. This method has demonstrated robustness and speed in generating novel monoclonal antibodies against a wide range of target molecules. For more information on QMAb™, please see our services.
Careers
Awards
Our commitment to innovation is deeply ingrained in our company’s core values. This is exemplified by our track record of achieving multiple SBIR (Small Business Innovation Research) grants and contracts from the National Institute of Health (NIH) and the Center for Disease Control and Prevention (CDC). We were able to leverage our innovative technology to develop new antibody reagents with great potential for use in research and diagnostics. The following is a comprehensive list of the grants and contracts we have been awarded in recent years.
| Award Type | Agency | Title | Period |
|---|---|---|---|
| SBIR Phase I contract | NIAID | Affinity Reagents for the Immune System of Swine | 09/30/2022 – 09/29/2024 |
| SBIR Phase I contract | NIAID | Affinity Reagents for the Immune System of Golden Hamster | 09/30/2022 – 09/29/2024 |
| SBIR Phase I contract | NCI | Rapid At-Home Detection for Serologic Status of HCV Infection | 09/19/2022 – 09/18/2023 |
| SBIR Phase I contract | NIAID | Point-of-Care HCV Core Antigen Detection | 08/31/2021 – 09/01/2022 |
| SBIR Phase I contract | NIAID | Affinity Reagents for the Immune System of Guinea Pigs | 08/01/2021 – 07/31/2022 |
| RADx Subaward through UC-CAI | NIH | Point-of-Care Antigen Detection for SARS-COV-2 from Saliva | 09/01/2020 – 08/31/2021 |
| SBIR Phase I contract | NIAID | Affinity Reagents for the Immune System of Guinea Pigs | 07/01/2020 – 06/30/2021 |
| SBIR Phase I contract | NCI | Point of Care Diagnostics for Liver Flukes Opisthorchis viverrini and Clonorchis sinensis | 09/16/2019 – 09/15/2020 |
| SBIR Phase I contract | CDC | Developing Species-Specific Human Taeniasis Coproantigen Detection Immunoassays | 09/16/2018 – 09/15/2019 |
| SBIR Phase II contract | CDC | Immunoassay for Serological detection and quantification of Hepatitis B core antigen | 09/05/2017 – 09/04/2019 |
| SBIR Phase I contract | NIAID | Rapid Point of Care Detection for Serologic Status of Individuals for CMV and HSV Infection | 08/01/2017 – 07/31/2018 |
| SBIR Phase II contract | CDC | Rapid test for HCV core antigen | 09/28/2015 – 09/30/2017 |
| SBIR Phase I grant | NHLBI | Immunoaffinity Lateral Flow Assay Device for Diagnosis of Sickle Cell Disease | 08/06/2014 – 06/30/2016 |
| SBIR Phase I contract | CDC | Rapid test for HCV core antigen | 09/30/2014 – 03/30/2015 |
ISO17025 Accredited laboratory
Qoolabs’ commitment to reliability, repeatability, and stability of our processes and results has allowed us to serve our customers with competence across various industries. Qoolabs has demonstrated our expertise and professionalism. Our dedication to quality in laboratory testing and analytical services has led to our accreditation as an ISO 17025 laboratory. This accreditation recognizes Qoolabs as a leader in the antibody engineering and services sector. The company’s commitment to meeting international standards and providing the highest quality services is evident in this accomplishment. Clients can have confidence in the reliability of Qoolabs’ results.
Contact Us
Location
Carlsbad, CA 92008
info <at> qoolabs.com
Phone
(858) 348-0988